ESMO

Verzenio Plus Endocrine Therapy Improves Outcomes HR-Positive, HER2-Negative Breast Cancer

October 20th 2023, 9:00pm

Article

Some patients with breast cancer who took Verzenio plus endocrine therapy two years after initial treatment demonstrated improved efficacy.

Immunotherapy With Tarlatamab May Improve Responses in Previously Treated SCLC

October 20th 2023, 7:00pm

Article

Patients with previously treated small cell lung cancer who received a 10-mg dose of tarlatamab had improved responses with no new safety signals.

Lumakras Improves Outcomes, Quality of Life in Patients With Lung Cancer Subtype

September 14th 2022, 7:00pm

Article

Lumakras outperformed chemotherapy in reducing the risk of progression or death and improving quality of life for patients with KRAS G12C-mutated non-small cell lung cancer, study results showed.

Presurgical Opdivo-Yervoy Combo Has ‘Very Strong Potential’ to Be Standard of Care for Subgroup of Patients With Colon Cancer

September 14th 2022, 3:00pm

Article

None of the more than 100 evaluable patients with mismatch repair deficient colon cancer have experienced disease recurrence after treatment with presurgical Opdivo plus Yervoy, according to study results.

Second-Line Treatment With Libtayo May Improve Long-Term Survival in Subset of Patients With Cervical Cancer

September 14th 2022, 1:00pm

Article

Treatment with Libtayo may improve survival over a 30-month period with no new side effects in patients with recurrent or metastatic cervical cancer, opening the doors for an immunotherapy option for these patients.

Longer Hormone Therapy After Main Treatments Delays Prostate Cancer Metastasis

September 13th 2022, 7:00pm

Article

Two years of the hormone treatment androgen-deprivation therapy (ADT) after radiotherapy and radical prostatectomy tended to improve metastasis-free survival for patients with prostate cancer, study results showed.

Tumor-Infiltrating Lymphocyte Decreases Death Risk in Unresectable Skin Cancer

September 13th 2022, 1:12pm

Article

The use of a tumor-infiltrating lymphocyte therapy led to better outcomes than treatment with Yervoy in patients with unresectable, treatment-refractory stage 3/4 melanoma, a type of skin cancer, study results showed.

Adding Keytruda to a Combination of Abiraterone Acetate Plus Prednisone Continues to Demonstrate Anti-Tumor Activity in a Group of Patients With Prostate Cancer

September 12th 2022, 7:04pm

Article

With nearly one-year of additional follow-up, adding Keytruda to the combination of abiraterone acetate and the steroid prednisone shows continued benefit in men with metastatic castration-resistant prostate cancer.

Adding Cabometyx to Immunotherapy Combination Improves Outcomes for Advanced Kidney Cancer

September 12th 2022, 3:00pm

Article

The addition of Cabometyx to the current standard-of-care frontline regimen of Opdivo plus Yervoy improved progression-free survival outcomes in patients with advanced kidney cancer.

Lenvima Plus Keytruda Bests Chemotherapy for Advanced Endometrial Cancer

September 12th 2022, 1:04pm

Article

Lenvima plus Keytruda improved survival outcomes for patients with pretreated advanced endometrial cancer, according to recent clinical trial data.